Targeting a specific molecular mechanism in brain tumors in children
A molecular informed therapy for Diffuse Intrinsic Pontine Gliomas (DIPG)
This study is looking at a new treatment for a tough brain tumor called DIPG that mostly affects kids, by exploring how certain changes in the tumor cells can help us use special drugs to slow down or stop the tumor from growing.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10906265 on NIH RePORTER |
What this research studies
This research investigates a novel therapy for Diffuse Intrinsic Pontine Gliomas (DIPG), a type of brain tumor that primarily affects children. By studying the molecular characteristics of tumor cells, particularly focusing on the H3K27M mutation and its interaction with acetylation, the research aims to develop a treatment strategy using BET bromodomain inhibitors. These inhibitors have shown promise in reducing tumor growth in preclinical models, and the research will explore ways to enhance their effectiveness and overcome resistance mechanisms. The ultimate goal is to establish a reliable treatment option for children diagnosed with DIPG.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with Diffuse Intrinsic Pontine Gliomas, particularly those with the H3K27M mutation.
Not a fit: Patients with other types of brain tumors or those without the H3K27M mutation may not benefit from this specific research.
Why it matters
Potential benefit: If successful, this research could lead to a new standard-of-care treatment for children with DIPG, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown success with similar approaches using BET inhibitors in preclinical models, indicating potential for effective treatment strategies.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Piunti, Andrea — University of Chicago
- Study coordinator: Piunti, Andrea
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.